Twenty companies raised $1.48 billion in follow-ons in January - the second most raised for that month in 20 years. January follow-ons priced at a median discount of about 5% compared with the price prior to the announcement of the proposed deal. Of the 20 deals, six priced more than two weeks after their initial filings. Akers Biosciences Inc. (LSE:AKR; NASDAQ:AKER), Aratana Therapeutics Inc. (NASDAQ:PETX), GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Receptos Inc. (NASDAQ:RCPT) and Retrophin Inc. (NASDAQ:RTRX) all priced